Both companies will collaborate to offer drug discovery and development services and to advance a common internal pipeline of drug development projects.
Licensing agreement grants Oculis exclusive global rights to develop and commercialize ACT-01, a potentially disease modifying therapy to protect and prevent damage to the optic nerve and retina.
The funding has been obtained through the Neotec programme, managed by the Spanish Ministry of Science and Innovation Centre for the Development of Industrial Technology (CDTI), in its 2021 call for projects.
CTH120, designed using artificial intelligence techniques, will start Phase I in 2022. CTH120 designation as orphan drug validates and empowers Connecta Therapeutics's strategy in neurodevelopmental diseases
Prous Institute for Biomedical Research is to present the 2020 Prous Institute – Overton & Meyer Award to Professor Gisbert Schneider, at the XXVI International Symposium on Medicinal Chemistry organized by the European Federation of Medicinal Chemistry (EFMC). The award, conferred every two years, recognizes…
Expanding and integrating drug toxicity data and translational safety intelligence from OFF-X into all
aspects of the life science cycle, allowing customers to make more informed decisions
The agreement aims to evaluate new approaches to enhance safety assessments of human pharmaceuticals and their associated molecular targets, supporting the FDA’s mission of protecting public health.
In under 12 months, the collaboration between Chemotargets and Galyan Bio has yielded a scaffold for first-in-class clinical candidates in a difficult area of neurodegenerative disease. Proprietary AI-driven de novo drug design methods were employed to rapidly design novel molecules which would bind to the previously ’undruggable’ Huntington’s disease target.
Groundbreaking AI tool brings analytical processes into one suite for radiologists, an industry first
The effects of ACT-01 on the thickness of retinal layers and clinical vision parameters will be evaluated in 36 patients with acute optic neuritis over 6- and 12-month periods.
The public-private consortium has obtained a grant of €1.97 million from the Spanish National Innovation Agency. Preclinical studies have shown that the CTH120 molecule can modulate neuroplasticity, the ability of cells of the nervous system to regenerate in response to pathological influences.
Connecta Therapeutics has closed a €1.7million round of investment led by Inveready that will allow the company to take its first drug through to phase IIa clinical trials in patients who have fragile X syndrome (FXS). CDTI and the biotechnology company’s founders also participated.
The platform allows early detection of COVID-19 by radiologists through imaging biomarkers and is the main AI platform for screening for the virus across Europe. The investment will enable QUIBIM to expand the range of algorithms and high-value components available through their platform.
The agreement aims to evaluate new approaches to enhance safety assessments of human pharmaceuticals and their associated molecular targets, supporting the FDA’s mission of protecting public health.
The public-private partnership with the IMIM Hospital del Mar Medical Research Institute will establish a framework for collaboration, combining Chemotargets’ know-how in drug discovery and development and IMIM’s experience in identifying new therapeutic targets in emerging fields of cancer biology.
OFF-X has become the largest translational safety and toxicity intelligence portal for drugs and targets of pharmacological interest. Launched in 2017, OFF-X has now reached 500,000 curated safety alerts corresponding to almost 15,000 targets of pharmacological interest and almost 14,500 drugs and biologics.
The Seal of Excellence certifies the high quality of the CLARITY proposal aimed at enhancing its data coverage, artificial intelligence approaches and analytics tools for drug discovery.
Announced today, the Vall d´Hebron Institute of Oncology - Bioinfogate collaboration will validate the utility of the OFF-X translational safety intelligence portal in the design of novel clinical trials, including first-in-human studies.
Virtual reality headsets that put domestic violence perpetrators in their victim’s shoes are set to be trialed in Britain after scientists found it cuts re-offending.
Under this MTA, the FDA has agency-wide access to Bioinfogate’s translational safety intelligence portal, OFF-X.
Dr Septien brings extensive experience in CNS conditions to neuroprotection biotech
Bioinfogate will cross-link the OFF-X translational safety intelligence portal with the Cortellis suite of solutions from Clarivate Analytics to enable enhanced insights for targets and drugs of interest.